Endocannabinoids and related fatty acid derivatives in pain modulation.                    (abst – 2002)


Characterisation of the vasorelaxant properties of the novel endocannabinoid N- arachidonoyl-dopamine (NADA).                                                                                (full – 2004)









TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N- arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.           (abst – 2004)                      


Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. (full – 2005)                             


Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N- arachidonoyldopamine (NADA) in the rat isolated aorta. (abst – 2005)


Targeted lipidomics: fatty acid amides and pain modulation.                      (abst – 2005)


Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.                                                           (abst – 2007)


N-                            arachidonoyl dopamine is a possible factor of the rate of tentacle formation in freshwater hydra                  (abst – 2008) 


The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine                                                    (full – 2009)


The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)). (abst – 2012)


The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes

(abst – 2012)              

Share a link for